BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1558 related articles for article (PubMed ID: 19515182)

  • 1. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
    Blonde L; Merilainen M; Karwe V; Raskin P;
    Diabetes Obes Metab; 2009 Jun; 11(6):623-31. PubMed ID: 19515182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
    Rosenstock J; Davies M; Home PD; Larsen J; Koenen C; Schernthaner G
    Diabetologia; 2008 Mar; 51(3):408-16. PubMed ID: 18204830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
    Garber AJ; Wahlen J; Wahl T; Bressler P; Braceras R; Allen E; Jain R
    Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes.
    Fogelfeld L; Dharmalingam M; Robling K; Jones C; Swanson D; Jacober S
    Diabet Med; 2010 Feb; 27(2):181-8. PubMed ID: 20546262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
    Meneghini L; Koenen C; Weng W; Selam JL
    Diabetes Obes Metab; 2007 Nov; 9(6):902-13. PubMed ID: 17924873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.
    Davies M; Lavalle-González F; Storms F; Gomis R;
    Diabetes Obes Metab; 2008 May; 10(5):387-99. PubMed ID: 18355327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study.
    Selam JL; Koenen C; Weng W; Meneghini L
    Curr Med Res Opin; 2008 Jan; 24(1):11-20. PubMed ID: 18021495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial.
    Liebl A; Prager R; Binz K; Kaiser M; Bergenstal R; Gallwitz B;
    Diabetes Obes Metab; 2009 Jan; 11(1):45-52. PubMed ID: 18643839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
    Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes.
    Raskin P; Gylvin T; Weng W; Chaykin L
    Diabetes Metab Res Rev; 2009 Sep; 25(6):542-8. PubMed ID: 19565569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fasting plasma glucose 6-12 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis.
    Karl D; Zhou R; Vlajnic A; Riddle M
    Diabet Med; 2012 Jul; 29(7):933-6. PubMed ID: 22413808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
    Janka HU; Plewe G; Busch K
    J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telecare Provides comparable efficacy to conventional self-monitored blood glucose in patients with type 2 diabetes titrating one injection of insulin glulisine-the ELEONOR study.
    Del Prato S; Nicolucci A; Lovagnini-Scher AC; Turco S; Leotta S; Vespasiani G;
    Diabetes Technol Ther; 2012 Feb; 14(2):175-82. PubMed ID: 22013886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.
    Bosi E; Dotta F; Jia Y; Goodman M
    Diabetes Obes Metab; 2009 May; 11(5):506-15. PubMed ID: 19320662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
    Dornhorst A; Lüddeke HJ; Koenen C; Meriläinen M; King A; Robinson A; Sreenan S;
    Diabetes Obes Metab; 2008 Jan; 10(1):75-81. PubMed ID: 18034846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.
    Raskin P; Allen E; Hollander P; Lewin A; Gabbay RA; Hu P; Bode B; Garber A;
    Diabetes Care; 2005 Feb; 28(2):260-5. PubMed ID: 15677776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 78.